Home
    • Plans Blog Contact
    10X Genomics Inc logo

    10X Genomics Inc

    TXG
    Last price US$46.27
    Market cap US$5.9b
    12M price change 236.75%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    National Research CorpNRC Industry peer HealthStream IncHSTM Industry peer VEEVA SYSTEMS INCVEEV Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    10X Genomics Inc Overview

    Industry: Health Information Services

    Sector: Healthcare

    10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California. 10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluid Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for 10X Genomics Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 07, 2026

    Quarterly result summary

    Revenue was $150.8M (reported). Net loss was -$13.5M (from $34.4M). Cash was $539.8M.

    Revenue $150.8M reported
    Net loss -$13.5M from $34.4M
    Cash $539.8M reported

    What changed

    • Revenue reported to $150.8M.
    • Net loss was -$13.5M (from $34.4M).

    Guidance / outlook

    The Company expects to start shipping Atera in the second half of 2026. • Announced a partnership with Bioptimus, a global AI biotech company, to launch STELA, a multinational spatial data generation initiative to create foundational datasets connecting underlying biology with disease outcomes.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q May 08, 2026 SEC filing 8-K May 07, 2026 SEC filing 10-K Feb 13, 2026 SEC filing 8-K Feb 12, 2026 Earnings release Earnings release Feb 12, 2026 SEC filing 8-K Jan 12, 2026 Earnings release Earnings release Jan 12, 2026 SEC filing 10-Q Nov 07, 2025 Earnings release Earnings release Nov 06, 2025 SEC filing 8-K Nov 06, 2025 SEC filing 10-Q Aug 08, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 2.00/5
    10X Genomics Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Health Information Services industry , National Research Corp , HealthStream Inc , VEEVA SYSTEMS INC are companies with high ratings.

    Return on Equity

    Score 1.76/5
    10X Genomics Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    10X Genomics... TXG US$5.9b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 1.95/5
    10X Genomics Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    10X Genomics... TXG US$5.9b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Health Information Services industry , National Research Corp , HealthStream Inc , VEEVA SYSTEMS INC are companies with high ratings.

    Leverage

    Score 3.14/5
    10X Genomics Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    10X Genomics... TXG US$5.9b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    10X Genomics Inc logo

    10X Genomics Inc

    US$46.27

    US$16.20

    -65.0% vs price

    US$5.9b

    5.78%

    236.75%